Key result
Ivabradine treatment in a patient with resistant postural orthostatic tachycardia syndrome reduced the Fatigue Impact Score from 102 to 52 and the orthostatic grading scale from 19 to 9.
Why the study?
Does ivabradine improve symptoms and heart rate in a patient with resistant postural orthostatic tachycardia syndrome?
Case Report (n=1)
Does ivabradine improve symptoms and heart rate in a patient with resistant postural orthostatic tachycardia syndrome?
Ivabradine may be an effective treatment for reducing tachycardia and improving debilitating symptoms like fatigue in patients with resistant postural orthostatic tachycardia syndrome.
Answers are grounded in this paper and cite their sources.
May support ivabradine in refractory POTS; single-case data leave open efficacy in controlled trials.
Here, we present a patient diagnosed with chronic fatigue syndrome/myalgic encephalomyelitis at the age of 15. She presented at that age with sudden onset of symptomatic palpitations after a viral illness. Over a period of days, she subsequently developed debilitating fatigue. Thyroid function tests and catecholamines were normal. Twelve lead ECG confirmed sinus tachycardia. She was referred to our Tertiary referral Cardiovascular Investigation unit at the age of 21. At that time, her fatigue score (measured by Fatigue Impact Score (FIS) (range 0–160)) was 102 and orthostatic grading scale (OGS) 19 (range 0–20). Active stand confirmed the diagnosis of postural orthostatic tachycardia syndrome (POTS) (increase of >30 bpm from baseline or greater than 120 bpm within 10 min of standing in the absence of postural hypotension and demonstrable autonomic neuropathy) ( Figure 1 A ). She was unable to tolerate beta-blockers (asthma) and verapamil (nausea). Despite conservative, non-pharmacologic treatment including volume expansion her symptoms persisted. Use of the sinus node blocker ivabradine at a dose of 2.5 mg twice daily and subsequently 5 mg twice daily led to dramatic improvements in subjective and objective symptomatology (FIS 52, OGS 9) in line with a reduction in heart rate on standing ( Figure 1 B ). conclusion: This case highlights the potential for the sinus node blocker ivabradine in the treatment of resistant POTS. Use of this medication appears to not only improve tachycardia but also symptomatology, including fatigue. A randomised controlled trial is needed. Continuous heart rate (25 mm/s) and blood pressure (Taskforce;CNSystems, Austria) in a patient with POTS and fatigue before ( A ) and after ( B ) treatment with 5 mg b.d of ivabradine. Standing is shown by red arrow. The patient has given consent for the use of these images, this can be provided on request. All authors participated in writing of this article. Conflict of interest : none declared.
No takes yet. Share an insight, caveat, or question.
Ewan et al. (2007) conducted a case report in Postural orthostatic tachycardia syndrome (POTS) (n=1). Ivabradine was evaluated on Symptomatology (Fatigue Impact Score and orthostatic grading scale) and heart rate on standing. Ivabradine treatment in a patient with resistant postural orthostatic tachycardia syndrome reduced the Fatigue Impact Score from 102 to 52 and the orthostatic grading scale from 19 to 9.
Synapse has enriched 10 related papers. Consider them for comparative context: